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The term “relapse carcinoma” is used improperly to
indicate either a local or loco-regional relapse or a sys-
tematic metastatsis [1]. Local relapse (LR) after thyroi-
dectomy for cancer is “the repetition of the neoplastic
lesion in proximity of the previous intervention of exci-
sion” [2]. According to Duren [3] relapses of thyroidal
carcinoma need to be classified as: local (LR): that may
present itself in the residual thyroid lobe or in the thyr-
oid bed where surgery was performed; loco-regional
(RLR): that may present in the cervical lymph nodes of
the central compartment or lateral-cervical nodes; and
metastasis in distance (MD). The MD are frequently
synchronous with LR or RLR; they have haematogenous
genesis and concern most frequently the lungs and
skeleton.
There is controversy over how to catergorize the
relapse in the thyroidal bed with infiltrations of neigh-
bouring organs (periodontal structures - muscles, thyroi-
dal cartilage, cricoid, laryngeal nerves, etc. and the
neighbouring organs - oesophagus, trachea, larynx). As
per the classification prop o s e db yD u r e n[ 3 ]t h e s e
should be considered as LR, whereas according to Moz-
zillo and Pezzullo [1] they are categorised as RLR.
The RLR at the level of the cervical lymphnodal sta-
tions represents an ulterior problem: are these true
relapses, residual cancer, or recurrence in progression?
Caracò [4], in his report to the ninety-fourth Congress
of the Italian Society of Surgery, specified that local
recurrences are only those recurrences that are charac-
terized by the appearance of neoplastic tissue in the
thyroidal lodge, in the residual parenchyma, and in the
adjacent structures, excluding the lymph nodes [5,6].
I nn e a r l y5 3 %o fc a s e st h er e l a p s ei sr e p o r t e di nR L R ,
in 28% in LR, and in 13% the MD is present of these 6%
of cases have mixed relapses [7]; the prognosis of LR is
however, better than that of the others [8]. The differen-
tiated tumors of the thyroid are slow growing and due
to this rarely reach notable dimensions or result in
metastasis in lymph and/or haematic systems [2]. Only
10% of patients die from differentiated thyroid cancer
[9].
Most of the local relapses occur within the first five
years of the excision of the primary cancer [5,6,10-12],
however, the recurrence can occur as late as 20 years
after the initial diagnosis and treatment [13]. An accu-
rate evaluation of incidence of LR is possible solely with
a considerable number of treated patients and lengthy
f o l l o w - u pt h a ti sn o ta v a i l a b l ea tm o s tc e n t r e sa n d
hence this kind of information can be obtained from the
date from centres that have high volume of thyroid car-
cinoma and good follow-up like Mayo Clinic or Lahey
Clinic [5,6,13] or through observational studies at sev-
eral other medical centres [14].
Currently relapses represent a rare event in patients
who undergo removal of thyroidal carcinoma (3-13%)
[5,6,10-12,15-17].
This is due to the ever increasing frequency of total
thyroidectomy for management of cancer [18]. The
complete excision of the thyroidal parenchyma prevents
local recurrence. Giovanni Razzaboni in “Treatise on
Prognostic Surgery” (1938) stated that “The most
rational operating method, so long as not free from
grave consequences of another kind, remains the total
extra-capsular thyroidectomy, so as is used, when possi-
ble, for the surgical removal of whatever other tumour”
[19]. he further emphasized in his work published after
his death in 1956 entitled “Treatise on Clinical Thera-
peutic Surgery” that “Only an removal of this capacity
justifies, in the face of a proven malignant tumour, sur-
gical intervention, any other incomplete or partial
demolition does nothing but accelerate the ready reoc-
currences, even in a very short time” [20].
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multiple. There exist a series of risk factors of local
relapse that correlate to the specific neoplastic illness, of
these the surgical treatment used, and use of adjuvant
therapies are most important.
Patients affected with thyroidal carcinoma are subdi-
vided into risk classes on the basis of the classification
systems AGES (Age, Grading, Extrathyroidal extension
and tumour size) (1987), AMES (Age, distant Metastasis,
Extra thyroidal extension and tumour Size) (1988) and
MACIS (distant Metastasis, Age, Completeness of resec-
tion, Invasion local, tumour Size) (1993) [21]. As per
these classifications low risk (mortality rate within 10
years of 1-2%)categories consists of men < 41 years and
women < 51 years, with well differentiated tumor and
tumors that are confined to the gland with absence of
regional or distant metastasis, or older patients without
extrathyroidal localization, either out of the thyroidal
capsule or at distance or without extrathyroidal localiza-
tion or out of the thyroidal capsule and patients with a
tumor <4 cm of maximum diameter. high risk on the
other hand (mortality rate within 10 years of 50-75%)are
classified as all patients that do not fall into the previous
category.
The most important risk factor in the onset of a local
relapse is the stage of the previous tumor, particularly
the local extension of the cancer and the involvement of
the lymphnodes. The diameter of the neoplasia with sig-
nificant risk of relapse varies from <1.5 cm (Schroder et
al.: 13/50 relapses in tumors of higher diameter vs 4/55
in patients with smaller tumor) Grant et al.reported 5%
of relapses within 20 years for tumours smaller then 4
cm vs 15% for larger tumours [5,6].
The spread of the cancer beyond the thyroidal capsule
is another important risk factor. In Mayo Clinic study
5% of patients with intracapsular cancer relapsed within
20 years against 15% relapse in patients with extracapsu-
lar cancer. In the Lahey Clinic study relapse rates were
higher at 52% (17/33) [13,22].
The presence of lymph node metastasis and follicular
carcinoma (7.3% in papillary tumours vs 29.3% in folli-
cular tumours in SICO trial) [14] are associated with an
increased risk of local relapse. Moreover the age of the
patient is an important variable with patietns over 45
years having higher mortality rates compared to younger
patients. On the other hand, multifocality does not
appear to be a significant risk factor in the development
of local recurrence in patients who undergo total thyroi-
dectomy (TT) or near total thyroidectomy (NTT) [23].
When LR appear they are associated with a poor prog-
nosis and around 33-50% of these patients will die due
to the resurgence of the illness [1]. With local relapse in
the residual thyroidal tissue the outcome is less grave,
compared to that involving the neighboring structures
[4]. Earlier relapses have been found to have poor prog-
nosis compared to late relapses (52.5% vs 85% [24].
In the past, at the 3-6 month the follow-up was con-
ducted with a total body scan using a diagnostic dose of
radio-iodine, TSH levels, thyroglobulin levels and anti-
tyreoglobulin antibodies. Currently, at the 3-6 month
follow up is conducted with ultrasound of the neck and
thyroglobulin measurements. The total body scan is no
longer performed as routine as it is unable to diagnose
the residual diseaseand provides no additonal informa-
tion that is already provided by the levels of tyroglobulin
after stimulation. The antityroglobulin antibodies esti-
mation have false positive rate of 6% and false negative
rate 1% [25].
Even at successive 6-12 month follow-up, only ultra-
sound and level of tyreoglbulin after stimulation with
recombinant TSH is recomended. In the absence of sus-
pected recurrence further ultrasound and biochemical
check-up are conducted at 6 monthly or yearly intervals
depending on the risk categories. In case of suspected
local recurrence further verifications with imaging (com-
puted tomography - CT- PET/CT, and/or total body
scan) is recomended [26].
In the location of relapse tumours of the thyroid the
sensitivity of TC ranges from 25 to 86% [25]. The mag-
netic resonance imaging (MRI) is particularly useful in
differentiating the neoplatic tissues from the postopera-
tive scar tissue [25]. The sensitivity of PET in the diag-
nosis of thyroidal carcinoma varies from 50 to 94%; it is
thus very useful in relapse cancers that do not take up
I
131. The accuracy of PET in anatomical locations is
now increased with the use of PET-CT [25], which
demonstrates a sensitivity of 80.7% and a specificity of
88.9% [27]. When the local recurrence or metastasis is
suspected an ultrasound guided needle biopsy can be
taken [1].
Currently the gold standard treatment for local relapse
of thyroidal cancer is the radiometabolic treament with
I
131. The possible cures that surgery may offers in local
recurrence is limited to selected cases [7]. Hence, surgi-
cal excision is advised only in cases of relapses that
were not or cannot be completely treated solely with the
radiometabolic treatment of I
131.
In absence of early detection of relapse the resectibil-
ity rates are poor [28], and surgical intervention is
marred by higher complecations [29,30].
The results of surgery seem to be better with local
recurrences without involvement of the contiguous tis-
sues; that constitute the minority of cases [4]. The use
of intraoperative ultrasound helps in identification of
the location of recurrent tumor and thus reduces the
extent of the cervical dissection; this results in less post-
operative complications. In patients who undergo
removal of the recurrence associated with cervical
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patients in which a cervical dissection is not conducted
(P = 0.0169) [31].
The results are not always disappointing; in fact Henri
Redon in his monograph “Indications chirurgicales dans
le traitements des cancers/Surgical Guidelines in the
Treatment of Cancers” (1962) wrote: “The question of
relapse. It must be re-operated and can give significant
results” [32].
The ERT (external radiotherapy) is reserved for
patients with inoperable relapse or tumors where I
131 is
assumed to be ineffective [33].
Considering all the above facts and poor response of
tumors to radio iodine and external therapy the multi
organ resection may be considered in this select group
of patients It could be a palliative resection in cases
where there is a invasion of the larynx, trachea, or both
organs. The infiltration of the larynx is often associated
with recurring paralysis for the contemporaneous inter-
est of a lower laryngeal nerve [34].
Conclusions
The survival of patients with local recurrence of dis-
ease in thyroid bed is better compated to those with
loco-regional or metastatic disease. Ablation of the
tumor by radio-iodine appears to be a better alterna-
tive however in select cases surgical resection can be
considered.
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